Advertisement

Gynäkologische Endokrinologie

, Volume 17, Issue 3, pp 139–147 | Cite as

Thrombophilieabklärung im Hinblick auf östrogenhaltige Kontrazeptiva und Hormonersatztherapie

  • M. Pollak
  • M. NaglerEmail author
Leitthema
  • 75 Downloads

Zusammenfassung

Östrogenhaltige Kontrazeptiva und eine Hormonersatztherapie werden weltweit von Millionen Frauen genutzt. Obwohl die Verträglichkeit generell sehr gut ist, besteht ein Risiko venöser und arterieller Thromboembolien. Im vorliegenden Beitrag werden nicht nur häufige Thrombophilien beschrieben, sondern Risikofaktoren für Thrombosen und Lungenembolien erklärt. Das thromboembolische Risiko unter verschiedenen Präparaten wird diskutiert und Risikofaktoren unter einer entsprechenden Therapie beschrieben. Zudem werden Handlungsanweisungen für die tägliche Praxis präsentiert.

Schlüsselwörter

Epidemiologie der venösen Thromboembolie Prävention der venösen Thromboembolie Unerwünschte Wirkungen kombinierter oraler Kontrazeptiva Unerwünschte Wirkungen der Östrogenersatztherapie Thrombophilieabklärung 

Thrombophilia, combined oral contraceptives and hormone replacement

Abstract

Combined oral contraceptives (COC) and hormone replacement treatment are used by millions of women worldwide due to the reliable contraception and other health benefits they offer. Although side effects are few, the treatment puts patients at risk for venous and atrial thromboembolism. The following article describes common thrombophilic situations and risk factors for deep vein thrombosis and pulmonary embolism. The thromboembolic risk of patients treated with different types of estrogen-containing drugs is summarized and related risk factors discussed. Guidance for use in clinical practice is also provided.

Keywords

Venous thromboembolism/epidemiology Venous thromboembolism/prevention and control Contraceptives, oral, combined/adverse effects Estrogen replacement therapy/adverse effects Thrombophilia/diagnosis 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

M. Pollak und M. Nagler geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Angelillo-Scherrer A, Nagler M (2016) Thrombophilieabklarung. Ther Umsch 73(10):626–634CrossRefPubMedGoogle Scholar
  2. 2.
    Nygaard K, Brown G (1937) Essential thrombophilia, report of five cases. Arch Intern Med 59:82–106CrossRefGoogle Scholar
  3. 3.
    Egeberg O (1965) Inherited Antithrombin deficiency causing Thrombophilia. Thromb Diath Haemorrh 13:516–530CrossRefPubMedGoogle Scholar
  4. 4.
    Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C (1981) Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68(5):1370–1373CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Comp PC, Esmon CT (1984) Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 311(24):1525–1528CrossRefPubMedGoogle Scholar
  6. 6.
    Dahlback B, Hildebrand B (1994) Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 91(4):1396–1400CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88(10):3698–3703CrossRefPubMedGoogle Scholar
  8. 8.
    Garcia D, Erkan D (2018) Diagnosis and management of the Antiphospholipid syndrome. N Engl J Med 378(21):2010–2021CrossRefPubMedGoogle Scholar
  9. 9.
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306CrossRefPubMedGoogle Scholar
  10. 10.
    Gando S, Levi M, Toh CH (2016) Disseminated intravascular coagulation. Nat Rev Dis Primers 2:16037CrossRefPubMedGoogle Scholar
  11. 11.
    Bushman JE, Palmieri D, Whinna HC, Church FC (2000) Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 24(7):559–565CrossRefPubMedGoogle Scholar
  12. 12.
    Kyrle PA, Rosendaal FR, Eichinger S (2010) Risk assessment for recurrent venous thrombosis. Lancet 376(9757):2032–2039CrossRefPubMedGoogle Scholar
  13. 13.
    Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev Cardiol 12(8):464–474CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158(6):585–593CrossRefPubMedGoogle Scholar
  15. 15.
    Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F et al (2012) Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e496SCrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Angelini D, Khorana AA (2017) Risk assessment scores for cancer-associated venous Thromboembolic disease. Semin Thromb Hemost 43(5):469–478CrossRefPubMedGoogle Scholar
  17. 17.
    Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G (2010) Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 170(19):1710–1716CrossRefPubMedGoogle Scholar
  18. 18.
    Nagler M, Ten Cate H, Prins MH, Ten Cate-Hoek AJ (2018) Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction. Res Pract Thromb Haemost 2(2):299–309CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Roach RE, Lijfering WM, Tait RC, Baglin T, Kyrle PA, Cannegieter SC, Rosendaal FR (2015) Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. J Thromb Haemost 13(10):1815–1822CrossRefPubMedGoogle Scholar
  20. 20.
    Eichinger S, Weltermann A, Minar E, Stain M, Schonauer V, Schneider B, Kyrle PA (2004) Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 164(1):92–96CrossRefPubMedGoogle Scholar
  21. 21.
    Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA (2003) D‑dimer levels and risk of recurrent venous thromboembolism. JAMA 290(8):1071–1074CrossRefPubMedGoogle Scholar
  22. 22.
    Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S et al (2006) D‑dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355(17):1780–1789CrossRefPubMedGoogle Scholar
  23. 23.
    Ensor J, Riley RD, Moore D, Snell KI, Bayliss S, Fitzmaurice D (2016) Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open 6(5):e11190CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    FSRH Guideline (2019) FSRH Guideline (January 2019) Combined Hormonal Contraception (Revision due by January 2024). BMJ Sex Reprod Health 45(Suppl 1):1–93CrossRefGoogle Scholar
  25. 25.
    Lidegaard O, Lokkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 339:b2890CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lekovic D, Miljic P, Dmitrovic A, Thachil J (2017) How do you decide on hormone replacement therapy in women with risk of venous thromboembolism? Blood Rev 31(3):151–157CrossRefPubMedGoogle Scholar
  27. 27.
    van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K (2016) Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 14(7):1393–1403CrossRefPubMedGoogle Scholar
  28. 28.
    Garcia D, Akl EA, Carr R, Kearon C (2013) Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 122(5):817–824CrossRefPubMedGoogle Scholar
  29. 29.
    Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e691S–e736SCrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Universitätsklinik für Hämatologie und Hämatologisches ZentrallaborInselspital UniversitätsspitalBernSchweiz
  2. 2.Universitäres Institut für Klinische ChemieInselspital Universitätsspital und Universität BernBernSchweiz
  3. 3.Universität BernBernSchweiz

Personalised recommendations